Polyisocyanates and their prepolymers

Asthma in the Workplace, Fourth Edition

Volumn , Issue , 2013, Pages 262-275

  Wisnewski, Adam V ^a   Redlich, Carrie A ^a   Mapp, Cristina E ^b   Bernstein, David I ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85131170794     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (172)

1. Redlich CA, Karol MH. Diisocyanate asthma: Clinical aspects and immunopathogenesis. Int Immunopharmacol 2002; 2: 213-24.
2. Mapp CE, Butcher BT, Fabbri LM. Polyisocyanates and their prepolymers. In: Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI, eds. Asthma in the Workplace, 2nd edn. New York: Marcel Dekker, 1999: 457-78.
3. Chan-Yeung M, Malo JL, Tarlo SM, et al. Proceedings of the first Jack Pepys Occupational Asthma Symposium. Am J Respir Crit Care Med 2003; 167: 450-71.
4. Urlich H. Chemistry and Technology of Isocyanates. West Sussex, England: John Wiley & Sons. Ltd, 1996.
5. Stowe M, Winewski AV, Holm CT, et al. Cross-Sectional Study of Auto Body Workers Exposed to Isocyanates: Immunologic Responses. Am J Resp Crit Care Med 2005; 171: 912-30.
6. Woskie SR, Sparer J, Gore RJ, et al. Determinants of isocyanate exposures in auto body repair and refinishing shops. Ann Occup Hyg 2004; 48: 393-403.
7. Sparer J, Stowe MH, Bello D, et al. Isocyanate exposures in autobody shop work: the SPRAY study. J Occup Environ Hyg 2004; 1: 570-81.
8. Lofgren DJ, Walley TL, Peters PM, Weis ML. MDI exposure for spray-on truck bed lining. Appl Occup Environ Hyg 2003; 18: 772-9.
9. Fabbri LM, Danieli D, Crescioli S, et al. Fatal asthma in a subject sensitized to toluene diisocyanate. Am Rev Respir Dis 1988; 137: 1494-8.
10. Redlich CA, Stowe MH, Coren BA, et al. Diisocyanate-exposed auto body shop workers: a one-year follow-up. Am J Ind Med 2002; 42: 511-18.
11. Redlich CA, Stowe MH, Wisnewski AV, et al. Subclinical immunologic and physiologic responses in hexamethylene diisocyanate-exposed auto body shop workers. Am J Ind Med 2001; 39: 587-97.
12. Tse KS, Johnson A, Chan H, Chan-Yeung M. A study of serum antibody activity in workers with occupational exposure to diphenylmethane diisocyanate. Allergy 1985; 40: 314-20.
13. Welinder H, Nielsen J, Bensryd I, Skerfving S. IgG antibodies against polyisocyanates in car painters. Clin Allergy 1988; 18: 85-93.
14. White WG, Morris MJ, Sugden E, Zapata E. Isocyanate-induced asthma in a car factory. Lancet 1980; 1: 756-60.
15. Carino M, Aliani M, Licitra C, Sarno N, Ioli F. Death due to asthma at workplace in a diphenylmethane diisocya-nate-sensitized subject. Respiration 1997; 64: 111-13.
16. Liss GM, Bernstein DI, Moller DR, et al. Pulmonary and immunologic evaluation of foundry workers exposed to methylene diphenyldiisocyanate (MDI). J Allergy Clin Immunol 1988; 82: 55-61.
17. Zammit-Tabona M, Sherkin M, Kijek K, Chan H, Chan-Yeung M. Asthma caused by diphenylmethane diisocyanate in foundry workers. Clinical, bronchial provocation, and immunologic studies. Am Rev Respir Dis 1983; 128: 226-30.
18. Petsonk EL, Wang ML, Lewis DM, Siegel PD, Husberg BJ. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 2000; 118: 1183-93.
19. Krone CA, Klingner TD, Ely JT. Polyurethanes and childhood asthma. Med Sci Monit 2003; 9: HY39-43.
20. http://www.bayer.com
21. Fuchs S, Valade P. Clinical and experimental study of some cases of poisoning by desmodur T (1-2-4 and 1-2-6 diisocyanates of toluene). Arch Mal Prof 1951; 12: 191-6.
22. Friebel H, Luchtrath H. Effects of toluylene diisocyanate (desmodur T) on the respiratory tract. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1955; 227: 93-110.
23. Swensson A, Holmquist CE, Lundgren KD. Injury to the respiratory tract by isocyanates used in making lacquers. Br J Ind Med 1955; 12: 50-3.
24. Woodbury JW. Asthmatic syndrome following exposure to tolylene diisocyanate. Ind Med Surg 1956; 25: 540-3.
25. Hama GM. Symptoms in workers exposed to isocyanates; suggested exposure concentrations. AMA Arch Ind Health 1957; 16: 232-3.
26. Johnstone RT. Toluene-2, 4-diisocyanate; clinical features. Ind Med Surg 1957; 26: 33-4.
27. Zapp JA Jr. Hazards of isocyanates in polyurethane foam plastic production. AMA Arch Ind Health 1957; 15: 324-30.
28. Walworth HT, Virchow WE. Industrial hygiene experiences with toluene diisocyanate. Am Ind Hyg Assoc J 1959; 20: 205-10.
29. Kessler RC. Pulmonary sensitization to toluene diisocyanate. J Occup Med 1960; 2: 143-7.
30. Elkins HB, Mc CG, Brugsch HG, Fahy JP. Massachusetts experience with toluene di-isocyanate. Am Ind Hyg Assoc J 1962; 23: 265-72.
31. Brugsch HG, Elkins HB. Toluene di-isocyanate (TDI) toxicity. N Engl J Med 1963; 268: 353-7.
32. Konzen RB, Craft BF, Scheel LD, Gorski CH. Human response to low concentrations of p,p-diphenylmethane diisocyanate (MDI). Am Ind Hyg Assoc J 1966; 27: 121-7.
33. Baur X, Chen Z, Marczynski B. Respiratory diseases caused by occupational exposure to 1,5-naphthalene-diisocya-nate (NDI): Results of workplace-related challenge tests and antibody analyses. Am J Ind Med 2001; 39: 369-72.
34. Diem JE, Jones RN, Hendrick DJ, et al. Five-year longitudinal study of workers employed in a new toluene diisocyanate manufacturing plant. Am Rev Respir Dis 1982; 126: 420-8.
35. Butcher BT, Jones RN, O'Neil CE, et al. Longitudinal study of workers employed in the manufacture of toluene-diiso-cyanate. Am Rev Respir Dis 1977; 116: 411-21.
36. Peters JM, Wegman DH. Epidemiology of toluene diisocyanate (TDI)-induced respiratory disease. Environ Health Perspect 1975; 11: 97-100.
37. Seguin P, Allard A, Cartier A, Malo JL. Prevalence of occupational asthma in spray painters exposed to several types of isocyanates, including polymethylene polyphenylisocyanate. J Occup Med 1987; 29: 340-4.
38. Bello D, Woskie SR, Streicher RP, et al. Polyisocyanates in occupational environments: A critical review of exposure limits and metrics. Am J Ind Med 2004; 46: 480-91.
39. Weill H. Disaster at Bhopal: the accident, early findings and respiratory health outlook in those injured. Bull Eur Physiopathol Respir 1987; 23: 587-90.
40. Vandenplas O, Malo JL, Saetta M, Mapp CE, Fabbri LM. Occupational asthma and extrinsic alveolitis due to isocyanates: current status and perspectives. Br J Ind Med 1993; 50: 213-28.
41. Mapp CE, Saetta M, Maestrelli P, Ciaccia A, Fabbri LM. Low molecular weight pollutants and asthma: pathogenetic mechanisms and genetic factors. Eur Respir J 1994; 7: 1559-63.
42. Luo JC, Nelsen KG, Fischbein A. Persistent reactive airway dysfunction syndrome after exposure to toluene diisocyanate. Br J Ind Med 1990; 47: 239-41.
43. Malo JL, Ghezzo H, D'Aquino C, et al. Natural history of occupational asthma: relevance of type of agent and other factors in the rate of development of symptoms in affected subjects. J Allergy Clin Immunol 1992; 90: 937-44.
44. Leroyer C, Perfetti L, Cartier A, Malo JL. Can reactive airways dysfunction syndrome (RADS) transform into occupational asthma due to "sensitisation" to isocyanates? Thorax 1998; 53: 152-3.
45. Butcher BT, Karr RM, O'Neil CE, et al. Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers. J Allergy Clin Immunol 1979; 64: 146-52.
46. Malo JL, Ghezzo H, Elie R. Occupational asthma caused by isocyanates: patterns of asthmatic reactions to increasing day-to-day doses. Am J Respir Crit Care Med 1999; 159: 1879-83.
47. Mapp CE, Boschetto P, Dal Vecchio L, Maestrelli P, Fabbri LM. Occupational asthma due to isocyanates. Eur Respir J 1988; 1: 273-9.
48. Malo J, Lemière C, Desjardins A, Cartier A. Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma. Eur Respir J 1997; 10: 1513-15.
49. Castano R, Gautrin D, Thériault C, et al. Occupational rhinitis in workers investigated for occupational asthma. Thorax 2009; 64: 50-4.
50. Perrin B, Cartier A, Ghezzo H, et al. Reassessment of the temporal patterns of bronchial obstruction after exposure to occupational sensitizing agents. J Allergy Clin Immunol 1991; 87: 630-9.
51. Malo J-L, Ouimet G, Cartier A, Levitz D, Zeiss R. Combined alveolitis and asthma due to hexamethylene diisocyanate (HDI), with demonstration of crossed respiratory and immunologic reactivities to diphenylmethane diisocyanate (MDI). J Allergy Clin Immunol 1983; 72: 413-19.
52. Vandenplas O, Malo JL, Dugas M, et al. Hypersensitivity pneumonitis-like reaction among workers exposed to diphenylmethane [correction to piphenylmethane] diisocyanate (MDI). Am Rev Respir Dis 1993; 147: 338-46.
53. Arrandale V, Liss G, Tarlo S, et al. Occupational contact allergens: are they also associated with occupational asthma? Am J Ind Med 2012; 55: 353-60.
54. Liu Y, Sparer J, Woskie SR, et al. Qualitative assessment of isocyanate skin exposure in auto body shops: a pilot study. Am J Ind Med 2000; 37: 265-74.
55. Pronk A, Yu F, Vlaanderen J, et al. Dermal, inhalation, and internal exposure to 1,6-HDI and its oligomers in car body repair shop workers and industrial spray painters. Occup Environ Med 2006; 63: 624-31.
56. Perfetti L, Brame B, Ferrari M, Moscato G. Occupational asthma (OA) with sensitization to diphenylmethane diisocyanate (MDI) presenting at the onset like a reactive airways dysfunction syndrome (RADS). Am J Ind Med 2003; 44: 325-8.
57. Séguin P, Allard A, Cartier A, Malo J. Prevalence of occupational asthma in spray painters exposed to several types of isocyanates, including polymethylene polyphenylisocyanates. JOM 1987; 29: 340-4.
58. Wisnewski A, Jones M. Pro/Con debate: is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease? Clin Exp Allergy 2010; 40: 1155-62.
59. Bernstein DI, Korbee L, Stauder T, et al. The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates. J Allergy Clin Immunol 1993; 92: 387-96.
60. Ott MG, Klees JE, Poche SL. Respiratory health surveillance in a toluene di-isocyanate production unit, 1967-97: clinical observations and lung function analyses. Occup Environ Med 2000; 57: 43-52.
61. Dragos M, Jones M, Malo J, Ghezzo H, Gautrin D. Specific antibodies to diisocyanate and work-related respiratory symptoms in apprentice car-painters. Occup Environ Med 2009; 66: 227-34.
62. Wegman D, Musk A, Main D, Pagnotto D. Accelerated loss of FEV-in polyurethane production workers: a four-year prospective study. Am J Ind Med 1982; 3: 209-15.
63. Clark RL, Bugler J, Paddle GM, Chamberlain JD, Allport DC. A 17-year epidemiological study on changes in lung function in toluene diisocyanate foam workers. Int Arch Occup Environ Health 2003; 76: 295-301.
64. Meyer J, Holt D, Chen Y, Cherry N, McDonald J. SWORD '99: Surveillance of work-related and occupational respiratory disease in UK. Occup Med 2001; 51: 204-8.
65. Larisa V, Buyantseva V, Liss G, et al. Reduction in Diisocyanate and Non-Diisocyanate Sensitizer-Induced Occupational Asthma in Ontario. J Occup Environ Med 2011; 53: 420-6.
66. Tarlo S, Liss G, Yeung K. Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures. Occup Environ Med 2002; 59: 58-62.
67. Kennedy AL, Wilson TR, Stock MF, Alarie Y, Brown WE. Distribution and reactivity of inhaled 14C-labeled toluene diisocyanate (TDI) in rats. Arch Toxicol 1994; 68: 434-43.
68. Kennedy AL, Stock MF, Alarie Y, Brown WE. Uptake and distribution of 14C during and following inhalation exposure to radioactive toluene diisocyanate. Toxicol Appl Pharmacol 1989; 100: 280-92.
69. Wisnewski AV, Srivastava R, Herick C, et al. Identification of human lung and skin proteins conjugated with hexamethylene diisocyanate in vitro and in vivo. Am J Respir Crit Care Med 2000; 162: 2330-6.
70. Monso E, Cloutier Y, Lesage J, Perreault G, Malo JL. What is the respiratory retention of inhaled hexamethylene diisocyanate? Eur Respir J 2000; 16: 729-30.
71. Liu Y, Berode M, Stowe MH, et al. Urinary hexane diamine to assess respiratory exposure to hexamethylene diisocyanate aerosol: a human inhalation study. Int J Occup Environ Health 2004; 10: 262-71.
72. Johannesson G, Sennbro CJ, Willix P, Lindh CH, Jonsson BA. Identification and characterisation of adducts between serum albumin and 4,4'-methylenediphenyl diisocyanate (MDI) in human plasma. Arch Toxicol 2004; 78: 378-83.
73. Sennbro CJ, Lindh CH, Tinnerberg H, et al. Development, validation and characterization of an analytical method for the quantification of hydrolysable urinary metabolites and plasma protein adducts of 2,4- and 2,6-toluene diisocyanate, 1,5-naphthalene diisocyanate and 4,4'-methyl-enediphenyl diisocyanate. Biomarkers 2003; 8: 204-17.
74. Wisnewski AV, Lemus R, Karol MH, Redlich CA. Isocya-nate-conjugated human lung epithelial cell proteins: A link between exposure and asthma? J Allergy Clin Immunol 1999; 104: 341-7.
75. Matheson JM, Lemus R, Lange RW, Karol MH, Luster MI. Role of tumor necrosis factor in toluene diisocyanate asthma. Am J Respir Cell Mol Biol 2002; 27: 396-405.
76. Mapp CE, Beghe B, Balboni A, et al. Association between HLA genes and susceptibility to toluene diisocyanate-induced asthma. Clin Exp Allergy 2000; 30: 651-6.
77. Nel AE, Slaughter N. T-cell activation through the antigen receptor. Part 2: role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy. J Allergy Clin Immunol 2002; 109: 901-15.
78. Nel AE. T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immunol 2002; 109: 758-70.
79. Bernstein DI, Kissling GE, Khurana Hershey G, et al. Hexamethylene diisocyanate asthma is associated with genetic polymorphisms of CD14, IL-13, and IL-4 receptor alpha. J Allergy Clin Immunol 2011; 128: 418-20.
80. Mapp CE. The role of genetic factors in occupational asthma. Eur Respir J 2003; 22: 173-8.
81. Piirila P, Wikman H, Luukkonen R, et al. Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure. Pharmacogenetics 2001; 11: 437-45.
82. Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109: 867-72.
83. Wikman H, Piirila P, Rosenberg C, et al. N-Acetyltransfer-ase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics 2002; 12: 227-33.
84. Berode M, Jost M, Ruegger M, Savolainen H. Host factors in occupational diisocyanate asthma: a Swiss longitudinal study. Int Arch Occup Environ Health 2005; 78: 158-63.
85. Yucesoy B, Johnson VJ, Lummus ZL, et al. Genetic variants in antioxidant genes are associated with diisocyanate-induced asthma. Toxicol Sci 2012; 129: 166-73.
86. Kim SH, Cho BY, Park CS, et al. Alpha-T-catenin (CTNNA3) gene was identified as a risk variant for toluene diisocyanate-induced asthma by genome-wide association analysis. Clin Exp Allergy 2009; 39: 203-12.
87. Bernstein DI, Kashon M, Lummus ZL, et al. CTNNA3 (alpha-catenin) gene variants are associated with diisocyanate asthma, a replication study in a Caucasian worker population. Toxicol Sci 2012; 131: 242-6.
88. Day BW, Jin R, Basalyga DM, Kramarik JA, Karol MH. Formation, solvolysis, and transcarbamoylation reactions of bis(S-glutathionyl) adducts of 2,4- and 2,6-diisocya-natotoluene. Chem Res Toxicol 1997; 10: 424-31.
89. Lange RW, Day BW, Lemus R, et al. Intracellular S-gluta-thionyl adducts in murine lung and human bronchoepi-thelial cells after exposure to diisocyanatotoluene. Chem Res Toxicol 1999; 12: 931-6.
90. Lantz RC, Lemus R, Lange RW, Karol MH. Rapid reduction of intracellular glutathione in human bronchial epithelial cells exposed to occupational levels of toluene diisocyanate. Toxicol Sci 2001; 60: 348-55.
91. Pauluhn J. Inhalation toxicity of 1,6-hexamethylene diisocyanate homopolymer (HDI-IC) aerosol: results of single inhalation exposure studies. Toxicol Sci 2000; 58: 173-81.
92. Pauluhn J. Acute inhalation toxicity of polymeric diphe-nyl-methane 4,4'-diisocyanate in rats: time course of changes in bronchoalveolar lavage. Arch Toxicol 2000; 74: 257-69.
93. Wisnewski AV, Liu J, Liu Q, Redlich CA. Glutathione protects human airway proteins and epithelial cells from isocyanates. Clin Exp Allergy 2005; 35: 325-7.
94. Rahman I, Gilmour PS, Jimenez LA, MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002; 234-235: 239-48.
95. Rahman I, Mulier B, Gilmour PS, et al. Oxidant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor-kappaB. Biochem Pharmacol 2001; 62: 787-94.
96. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16: 534-54.
97. Wisnewski AV, Liu Q, Miller JJ, Magoski N, Redlich CA. Effects of hexamethylene diisocyanate exposure on human airway epithelial cells: in vitro cellular and molecular studies. Environ Health Perspect 2002; 110: 901-7.
98. Iwata S, Hori T, Sato N, et al. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J Immunol 1997; 158: 3108-17.
99. Wakasugi N, Tagaya Y, Wakasugi H, et al. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 1990; 87: 8282-6.
100. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994; 1218: 292-6.
101. Elms J, Beckett PN, Griffin P, Curran AD. Mechanisms of isocyanate sensitisation. An in vitro approach. Toxicol In Vitro 2001; 15: 631-4.
102. Kim SH, Choi GS, Ye YM, et al. Toluene diisocyanate (TDI) regulates haem oxygenase-1/ferritin expression: implications for toluene diisocyanate-induced asthma. Clin Exp Immunol 2010; 160: 489-97.
103. Mishra PK, Khan S, Bhargava A, et al. Regulation of isocyanate-induced apoptosis, oxidative stress, and inflammation in cultured human neutrophils: isocyanate-induced neutrophils apoptosis. Cell Biol Toxicol 2010; 26: 279-91.
104. Wisnewski AV, Xu L, Robinson E, et al. Immune sensitization to methylene diphenyl diisocyanate (MDI) resulting from skin exposure: albumin as a carrier protein connecting skin exposure to subsequent respiratory responses. J Occup Med Toxicol 2011; 6: 6.
105. Redlich CA. Skin exposure and asthma: is there a connection? Proc Am Thoracic Soc 2010; 7: 134-7.
106. Lemiere C, Pelissier S, Tremblay C, et al. Leukotrienes and isocyanate-induced asthma: a pilot study. Clin Exp Allergy 2004; 34: 1684-9.
107. Maestrelli P, Calcagni PG, Saetta M, et al. Sputum eosinophilia after asthmatic responses induced by isocyanates in sensitized subjects. Clin Exp Allergy 1994; 24: 29-34.
108. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
109. Park H, Jung K, Kim H, Nahm D, Kang K. Neutrophil activation following TDI bronchial challenges to the airway secretion from subjects with TDI-induced asthma. Clin Exp Allergy 1999; 29: 1395-401.
110. Sastre J, Banks DE, Lopez M, Barkman HW, Salvaggio JE. Neutrophil chemotactic activity in toluene diisocyanate (TDI)-induced asthma. J Allergy Clin Immunol 1990; 85: 567-72.
111. Valentino M, Governa M, Fiorini R. Increased neutrophil leukocyte chemotaxis induced by release of a serum factor in toluene-diisocyanate (TDI) asthma. Lung 1988; 166: 317-25.
112. Fabbri LM, Boschetto P, Zocca E, et al. Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Respir Dis 1987; 136: 36-42.
113. Bentley AM, Maestrelli P, Saetta M, et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 1992; 89: 821-9.
114. Shi HZ, Li S, Xie ZF, et al. Regulatory CD4+CD25+ T lymphocytes in peripheral blood from patients with atopic asthma. Clin Immunol 2004; 113: 172-8.
115. Del Prete GF, De Carli M, D'Elios MM, et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23: 1445-9.
116. Maestrelli P, Del Prete GF, De Carli M, et al. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994; 20: 376-81.
117. Paggiaro P, Bacci E, Paoletti P, et al. Bronchoalveolar lavage and morphology of the airways after cessation of exposure in asthmatic subjects sensitized to toluene diisocyanate. Chest 1990; 98: 536-42.
118. Maestrelli P, Occari P, Turato G, et al. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate. Clin Exp Allergy 1997; 27: 1292-8.
119. Herrick CA, Xu L, Wisnewski AV, et al. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J Allergy Clin Immunol 2002; 109: 873-8.
120. Liu Q, Wisnewski AV. Recent developments in diisocyanate asthma. Ann Allergy Asthma Immunol 2003; 90: 35-41.
121. Wisnewski AV, Herrick CA, Liu Q, et al. Human gamma/ delta T-cell proliferation and IFN-gamma production induced by hexamethylene diisocyanate. J Allergy Clin Immunol 2003; 112: 538-46.
122. Jones MG, Floyd A, Nouri-Aria KT, et al. Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol 2006; 117: 663-9.
123. Redlich CA, Karol MH, Graham C, et al. Airway isocyanate-adducts in asthma induced by exposure to hexamethylene diisocyanate. Scand J Work Environ Health 1997; 23: 227-31.
124. Choi JH, Nahm DH, Kim SH, et al. Increased levels of IgG to cytokeratin 19 in sera of patients with toluene diisocyanate-induced asthma. Ann Allergy Asthma Immunol 2004; 93: 293-8.
125. Finotto S, Fabbri LM, Rado V, Mapp CE, Maestrelli P. Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate. Br J Ind Med 1991; 48: 116-21.
126. Bernstein JA, Munson J, Lummus ZL, Balakrishnan K, Lei-kauf G. T-cell receptor V beta gene segment expression in diisocyanate-induced occupational asthma. J Allergy Clin Immunol 1997; 99: 245-50.
127. Lummus ZL, Alam R, Bernstein JA, Bernstein DI. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy Clin Immunol 1998; 102: 265-74.
128. Bernstein DI, Cartier A, Cote J, et al. Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med 2002; 166: 445-50.
129. Bernstein DI, Jolly A. Current diagnostic methods for diisocyanate induced occupational asthma. Am J Ind Med 1999; 36: 459-68.
130. Rammazzini B. De Morbis Artifictum, Translated from Latin Text. New York: Hafner, 1964.
131. Pepys J, Hutchcroft BJ. Bronchial provocation tests in etiologic diagnosis and analysis of asthma. Am Rev Respir Dis 1975; 112: 829-59.
132. Darcey D, Lipscomb HJ, Epling C, et al. Clinical findings for residents near a polyurethane foam manufacturing plant. Arch Environ Health 2002; 57: 239-46.
133. Merget R, Marczynski B, Chen Z, et al. Haemorrhagic hypersensitivity pneumonitis due to naphthylene-1,5-dii-socyanate. Eur Respir J 2002; 19: 377-80.
134. Yoshizawa Y, Ohtani Y, Hayakawa H, et al. Chronic hypersensitivity pneumonitis in Japan: a nationwide epidemiologic survey. J Allergy Clin Immunol 1999; 103: 315-20.
135. Buick JB, Todd GR. Concomitant alveolitis and asthma following exposure to triphenylmethane triisocyanate. Occup Med (Lond) 1997; 47: 504-6.
136. Baur X. Hypersensitivity pneumonitis (extrinsic allergic alveolitis) induced by isocyanates. J Allergy Clin Immunol 1995; 95: 1004-10.
137. Bernstein DI, Korbee L, Stauder T, et al. The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates. J Allergy Clin Immunol 1993; 92: 387-96.
138. Campo P, Wisnewski AV, Lummus Z, et al. Diisocyanate conjugate and immunoassay characteristics influence detection of specific antibodies in HDI-exposed workers. Clin Exp Allergy 2007; 37: 1095-102.
139. Baur X, Chen Z, Flagge A, Posch A, Raulf-Heimsoth M. EAST and CAP specificity for the evaluation of IgE and IgG antibodies to diisocyanate-HSA conjugates. Int Arch Allergy Immunol 1996; 110: 332-8.
140. Baur X, Dewair M, Fruhmann G. Detection of immunologically sensitized isocyanate workers by RAST and intra-cutaneous skin tests. J Allergy Clin Immunol 1984; 73: 610-18.
141. Tee RD, Cullinan P, Welch J, Burge PS, Newman-Taylor AJ. Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101: 709-15.
142. Lushniak BD, Reh CM, Bernstein DI, Gallagher JS. Indirect assessment of 4,4'-diphenylmethane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin. Am J Ind Med 1998; 33: 471-7.
143. Lemus R, Lukinskeine L, Bier ME, et al. Development of immunoassays for biomonitoring of hexamethylene diisocyanate exposure. Environ Health Perspect 2001; 109: 1103-8.
144. Karol MH, Alarie Y. Antigens which detect IgE antibodies in workers sensitive to toluene diisocyanate. Clin Allergy 1980; 10: 101-9.
145. Karol MH, Hauth BA. Use of hexyl isocyanate antigen to detect antibodies to hexamethylene diisocyanate (HDI) in sensitized guinea pigs and in a sensitized worker. Fund Appl Toxicol 1982; 2: 108-13.
146. Karol MH, Alarie YC. Serologic test for toluene diisocyanate (TDI) antibodies [letter]. J Occup Med 1978; 20: 383.
147. Karol MH, Ioset HH, Alarie YC. Tolyl-specific IgE antibodies in workers with hypersensitivity to toluene diisocyanate. Am Ind Hyg Assoc J 1978; 39: 454-8.
148. Karol MH, Riley EJ, Alarie Y. Presence of tolyl-specific IgE and absence of IgG antibodies in workers exposed to toluene diisocyanate. J Environ Sci Health C 1979; 13: 221-32.
149. Karol MH, Sandberg T, Riley EJ, Alarie Y. Longitudinal study of tolyl-reactive IgE antibodies in workers hypersensitive to TDI. J Occup Med 1979; 21: 354-8.
150. Scheel LD, Killens R, Josephson A. Immunochemical Aspects of Toluene Diisocyanate (TDI) Toxicity. Am Ind Hyg Assoc J 1964; 25: 179-84.
151. Wisnewski AV, Stowe MH, Cartier A, et al. Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol 2004; 113: 1178-84.
152. Avery SB, Stetson DM, Pan PM, Mathews KP. Immunological investigation of individuals with toluene diisocyanate asthma. Clin Exp Immunol 1969; 4: 585-96.
153. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171: 54-60.
154. Mapp CE, Polato R, Maestrelli P, Hendrick DJ, Fabbri LM. Time course of the increase in airway responsiveness associated with late asthmatic reactions to toluene diisocyanate in sensitized subjects. J Allergy Clin Immunol 1985; 75: 568-72.
155. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 53-83.
156. Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10: 2612-29.
157. Mapp CE, Dal Vecchio L, Boschetto P, De Marzo N, Fabbri LM. Toluene diisocyanate-induced asthma without airway hyperresponsiveness. Eur J Respir Dis 1986; 68: 89-95.
158. Butcher BT, Hammad YY, Hendrick DJ. Occupational asthma: identification in the agent. In: Gee JBL, ed. Occupational Lung Disease. New York: Churchill Livingstone, 1984: 111.
159. Fabbri LM. Occupational Asthma. In: O'Byrne PM, ed. Asthma as an Inflammatory Disease. New York: Marcel Dekker, Inc, 1990.
160. Tarlo SM, Boulet LP, Cartier A, et al. Canadian Thoracic Society guidelines for occupational asthma. Can Respir J 1998; 5: 289-300.
161. Hammad YY, Rando RJ, Abdel-Kader H. Considerations in the design and use of human inhalation challenge delivery systems. Folia Allergol Immunol Clin 1985; 32: 37-44.
162. Nicholson PJ, Cullinan P, Taylor AJ, Burge PS, Boyle C. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62: 290-9.
163. Burge PS, O'Brien IM, Harries MG. Peak flow rate records in the diagnosis of occupational asthma due to isocyanates. Thorax 1979; 34: 317-23.
164. Perrin B, Lagier F, L'Archeveque J, et al. Occupational asthma: validity of monitoring of peak expiratory flow rates and non-allergic bronchial responsiveness as compared to specific inhalation challenge. Eur Respir J 1992; 5: 40-8.
165. Malo JL, Cartier A, Ghezzo H, Chan-Yeung M. Compliance with peak expiratory flow readings affects the within- and between-reader reproducibility of interpretation of graphs in subjects investigated for occupational asthma. J Allergy Clin Immunol 1996; 98: 1132-4.
166. Labrecque M, Malo J, Alaoui K, Rabhi K. Medical surveillance programme for diisocyanate exposure. Occup Environ Med 2011; 68: 302-7.
167. Vandenplas O, Dressel H, Nowak D, Jamart J. What is the optimal management option for occupational asthma?
168. ERS task force on the management of work-related asthma. Eur Respir Rev 2012; 21: 97-104.
169. Talini D, Novelli F, Melosini L, et al. May the reduction of exposure to specific sensitizers be an alternative to work cessation in occupational asthma? Results from a follow-up study. Int Arch Allergy Immunol 2012; 157: 186-93.
170. Piirila PL, Nordman H, Keskinen HM, et al. Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane diisocyanate-, and toluene diisocyanate-induced asthma. Am J Respir Crit Care Med 2000; 162: 516-22.
171. Malo J, L'archevêque J, Castellanos L, et al. Long-term outcomes of acute irritant-induced asthma. Am J Respir Crit Care Med 2009; 179: 923-8.
172. Malo J, Cartier A, Côté J, et al. Influence of inhaled steroids on the recovery of occupational asthma after cessation of exposure: an 18-month double-blind cross-over study. Am J Respir Crit Care Med 1996; 153: 953-60.